Related Experiment Video

Updated: Jun 29, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

A miRNA-7704/IL2RB/AKT feedback loop regulates tumorigenesis and chemoresistance in ovarian cancer

Xuan Meng1, Xiaoqing Liang2, Shengjie Yang3

  • 1Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; Department of Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China.

Experimental Cell Research
|April 2, 2024
PubMed

Insights

MicroRNA-7704 (miR-7704) combats ovarian cancer by inhibiting cell growth and enhancing cisplatin sensitivity. It targets IL2RB to inactivate the AKT pathway, offering potential therapeutic strategies for chemoresistant ovarian cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer is a leading gynecological malignancy with significant treatment challenges, particularly chemoresistance.
  • MicroRNAs (miRNAs) are key regulators in cancer development, influencing proliferation, differentiation, and drug resistance.
  • miR-7704 is notably downregulated in cisplatin-resistant ovarian cancer cells.

Purpose of the Study:

  • To investigate the role of miR-7704 in ovarian cancer proliferation and cisplatin sensitivity.
  • To elucidate the molecular mechanism underlying miR-7704's function in ovarian cancer.
  • To evaluate miR-7704 and IL2RB as potential therapeutic targets for ovarian cancer.

Main Methods:

  • Microarray and quantitative PCR (qPCR) analyses to assess miR-7704 expression.
  • In vitro and in vivo experiments to evaluate the effects of miR-7704 on ovarian cancer cell proliferation and cisplatin sensitivity.
  • Mechanistic studies involving IL2RB expression, AKT signaling pathway, and ectopic miR-7704 expression or IL2RB knockdown.

Main Results:

  • miR-7704 was significantly downregulated in cisplatin-resistant ovarian cancer cells.
  • Overexpression of miR-7704 inhibited ovarian cancer cell proliferation and increased sensitivity to cisplatin both in vitro and in vivo.
  • miR-7704 regulated IL2RB expression, leading to the inactivation of the AKT signaling pathway.
  • IL2RB knockdown mimicked the effects of miR-7704 overexpression, and IL2RB reversed miR-7704's effects on cisplatin resistance.

Conclusions:

  • miR-7704 functions as a tumor suppressor in ovarian cancer by inhibiting proliferation and enhancing cisplatin sensitivity.
  • The miR-7704/IL2RB axis regulates the AKT signaling pathway, impacting chemoresistance in ovarian cancer.
  • miR-7704 and IL2RB represent promising novel therapeutic targets for overcoming cisplatin resistance in ovarian cancer.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.3K
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K